Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1HP vs 3HP for Latent TB Infection in HIV-infected Individuals
NCT03785106Phase 3Active, not recruiting
- Sponsor
- HIV-NAT
- Start
- Aug 2019
- Primary completion
- Mar 2038
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isoniazid and rifapentine in latent tuberculosis infection (LTBI) (2 arms), sponsored by HIV-NAT. Primary endpoints: Efficacy in preventing active TB at 3 years, Safety of the regimens at 3 years and 2 more. Started Aug 2019; status: active, not recruiting.
02
Drugs
isoniazidrifapentine
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on NCT03785106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03785106.